

Platelet-Rich Fibrin in Bone Regeneration: A Systems Biology Approach to Mechanisms and Clinical Translation

Authors

ATAZHANOV SARDORBEB¹ MD, NAJEEB ULLAH² PhD, MAMATURSIN TURDI^{*3}

¹Department of oral and maxillofacial surgery

First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China

Email: sardor1696@qq.com

Phone: 17590155098

²Department of Endocrinology

First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China

Email: Najeebzarger@gmail.com

ORCID ID : 0009-0008-9663-1013

^{3*}Department of oral and maxillofacial surgery

First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China

Email: maimaitituxun@aliyun.com

Phone: 0086 991-4318351

Corresponding Author

^{*3}Professor MAMATURSIN TURDI

Department of oral and maxillofacial surgery

First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China

Email: maimaitituxun@aliyun.com

Phone: 0086 991-4318351

Abstract

Platelet-rich fibrin (PRF), a second-generation autologous platelet concentrate, represents a paradigm shift in regenerative biomaterials. Distinguished by its three-dimensional fibrin matrix, PRF orchestrates a sustained, sequential release of growth factors and cytokines, establishing a biomimetic osteogenic niche [1, 2]. This review systematically deconstructs the preparation-property-function relationship of PRF and its derivatives (L-PRF, A-PRF, i-PRF, T-PRF), linking centrifugal parameters to quantifiable scaffold architecture and release kinetics [3, 4]. A central thesis posits that PRF's efficacy stems from a tripartite mechanism: direct osteogenic programming of progenitor cells via BMP/Smad and MAPK/ERK pathways [5, 6]; potentiation of mature osteoblast function and matrix mineralization [7]; and strategic remodeling of the healing microenvironment through coupled angiogenesis and immunomodulation [8, 9]. Evidence-based clinical appraisal confirms its utility in oral and maxillofacial surgery, with data indicating a 35-50% enhancement in bone density and healing rates in procedures such as sinus augmentation and alveolar ridge preservation [10, 11]. However, clinical translation is impeded by protocol heterogeneity and suboptimal degradation kinetics [12]. We conclude by proposing a roadmap integrating engineered PRF composites with tunable properties and AI-optimized preparation protocols to transition PRF from a biological tool to a standardized, next-generation therapeutic platform [13, 14].

Keywords:

Platelet-Rich Fibrin; Bone Regeneration; Tissue Engineering; Growth Factors; Molecular Mechanisms; Clinical Translation; Standardization.

1. Introduction

The reconstruction of critical-sized bone defects remains a formidable clinical challenge, with significant socioeconomic burdens. Autologous bone grafting, the clinical gold standard, is constrained by donor-site morbidity, limited volume, and variable resorption rates [15]. Allogeneic and xenogeneic substitutes, while circumventing some limitations, present risks of immunogenicity, disease transmission, and often lack intrinsic osteoinductive capacity [16]. This therapeutic gap has propelled the development of bioactive materials designed to recapitulate the natural healing cascade. Among these, platelet concentrates have evolved significantly. First-generation platelet-rich plasma (PRP), limited by rapid growth factor burst release and the need for anticoagulants, has been superseded by platelet-rich fibrin (PRF) [17]. Prepared via single-step centrifugation without biochemical additives, PRF forms an autologous fibrin scaffold enriched with platelets, leukocytes, and the full complement of circulating cytokines [18]. Its defining advantage is a gradual, biologically coherent release profile of key morphogens over 7-21 days, aligning with the early inflammatory and proliferative phases of bone repair [19, 20]. This review moves beyond descriptive cataloguing to provide a systems-level analysis. We aim to: (1) establish a quantitative link between centrifugation physics, matrix ultrastructure, and bioactivity; (2) synthesize the complex, interdependent molecular pathways through which PRF directs osteogenesis; (3) critically appraise clinical efficacy using hierarchical evidence grading; and (4) outline a translational roadmap leveraging biomaterials science and data-driven optimization to overcome existing limitations.

2. The PRF Platform: From Centrifugation Parameters to a Tunable Biomaterial

The biological performance of PRF is not intrinsic but is engineered through its preparation protocol. Variations in relative centrifugal force (RCF), time, and tube material directly dictate the fibrin network's density, cellular distribution, and resultant growth factor sequestration [21, 22].

Table 1. Classification, preparation protocols, and characteristic biological properties of principal platelet-rich fibrin (PRF) derivatives. Protocols are based on representative studies; variations in centrifuge type and tube material can alter final composition. Abbreviations: L-PRF (Leukocyte- and Platelet-Rich Fibrin), A-PRF (Advanced Platelet-Rich Fibrin), i-PRF (Injectable Platelet-Rich Fibrin), T-PRF (Titanium-Prepared Platelet-Rich Fibrin).

Type	Protocol (Representative)	Key Structural Features	Growth Factor Release Kinetics	Primary Clinical Indications
L-PRF (Leukocyte- & PRF)	2700 rpm, 12 min, glass/silica-coated tubes [23]	Dense, multi-layered fibrin clot; high platelet/leukocyte concentration in buffy coat.	Sustained release over 14-21 days; high TGF- β 1, PDGF-BB [24].	GBR membranes, sinus floor augmentation, extraction socket management.
A-PRF (Advanced PRF)	1500 rpm, 14 min [25]	Looser, more homogeneous fibrin network; broader cell distribution.	Increased initial release (Day 1-3); favorable VEGF profile [26].	Soft tissue healing, periodontal defects, as a liquid additive to grafts.

i-PRF (Injectable PRF)	700 rpm, 3 min [27]	Liquid phase; sparse fibrin polymerisation.	Very high initial burst (<60 min); short duration (<7 days) [28].	Intramedullary injection, composite graft hydration, superficial ulcers.
T-PRF (Titanium-PRF)	Standard L-PRF protocol with titanium tubes [29]	Nanoscale titanium particles integrated into fibrin; increased tensile strength [30].	Release kinetics similar to L-PRF with added pro-osteogenic ionic release [31].	Peri-implant defects, osteoporotic bone models, infected sites.




Figure 1. The centrifugation-scaffold-release continuum in PRF. (A) Simulated growth factor release kinetics over a 14-day period for different PRF derivatives, illustrating the spectrum from rapid burst release (i-PRF) to sustained, prolonged release (L-PRF, T-PRF). (B) Schematic relationship between relative centrifugal force (RCF, conceptual), the resulting fibrin network density, and platelet entrapment efficacy, which collectively determine the scaffold's mechanical strength and biochemical release profile.

3. Molecular Mechanisms: A Synergistic Network Driving Osteogenesis

PRF does not act via a single pathway but coordinates a multifaceted regenerative program.

3.1. Directing Stem Cell Fate: From Migration to Osteogenic Commitment

The fibrin matrix serves as a haptotactic scaffold—that is, a scaffold with spatially organized adhesive cues that direct cell migration—for mesenchymal stem cells (MSCs), facilitating adhesion via integrin binding ($\alpha v \beta 3$) and activating focal adhesion kinase (FAK) signaling [32]. The sustained biochemical stimulus is critical. TGF- $\beta 1$ within PRF has been shown to upregulate endogenous BMP-2 expression in MSCs and resident fibroblasts, activating the canonical BMP/Smad1/5/8 pathway—a master regulator of osteoblast differentiation [5, 33]. Simultaneously, PDGF and other factors activate the MAPK/ERK pathway, which phosphorylates and stabilizes the key osteogenic transcription factor Runx2 [6, 34]. This synergistic signaling ensures both proliferation (via ERK) and lineage specification (via Smad). PRF's sustained release likely maintains this signaling above a critical threshold, a distinct advantage over PRP's transient peak [35]. Evidence also implicates Wnt/ β -catenin pathway crosstalk,

particularly in chondrogenic priming under mechanical load, relevant for endochondral ossification in larger defects [36].

3.2. Potentiating the Osteoblast Phenotype and Matrix Mineralization

PRF directly enhances the function of committed osteoblasts. In vitro, PRF-conditioned media significantly increases osteoblast proliferation, alkaline phosphatase (ALP) activity (an early differentiation marker), and the expression of late markers like osteocalcin (OCN) [7]. This is mediated not only by soluble factors (e.g., IGF-1) but also by matrix-derived signals. Osteoblast adhesion to the fibrin network further stimulates integrin-mediated ERK activation, creating a positive feedback loop that amplifies Runx2 activity and promotes cell survival [37]. Ultimately, this leads to enhanced extracellular matrix (ECM) deposition and mineralization. Quantitative micro-CT and histomorphometric analyses of in vitro nodules and in vivo specimens demonstrate a significant increase in bone volume/total volume (BV/TV) and mineral density in PRF-treated groups compared to controls [38, 39].

3.3. Remodeling the Regenerative Niche: Angiogenesis and Immunomodulation

Successful bone formation is exquisitely dependent on its microenvironment.

Angiogenesis : PRF is a reservoir for potent pro-angiogenic factors, including VEGF, PDGF, and TGF-β1. VEGF is the principal mediator, driving endothelial cell proliferation, migration, and tube formation [8]. The fibrin matrix itself provides a provisional template for capillary ingrowth. The co-release of PDGF supports the recruitment and stabilization of pericytes, essential for mature vessel formation [40]. This robust neovascularization ensures nutrient delivery, oxygen supply, and a conduit for additional osteoprogenitor cells [41].

Immunomodulation : The leukocyte component is a defining and functional element of L-PRF. It facilitates a controlled inflammatory phase. Neutrophils and monocytes within the clot provide initial antimicrobial defense [42]. More importantly, PRF shifts macrophage polarization from the pro-inflammatory M1 phenotype towards the pro-healing M2 phenotype. This is achieved through the release of cytokines like IL-4 and IL-10, which downregulate TNF-α and IL-1β [9, 43]. M2 macrophages promote tissue remodeling, clear apoptotic debris, and secrete pro-angiogenic factors like VEGF, creating a positive feedback loop with the vascularization process [44]. This modulated immune response prevents chronic inflammation and fibrosis, fostering a conducive environment for regeneration.

Figure 2: Integrated Systems Map of PRF-Mediated Osteogenesis

Figure 2: PRF Systems Map




Figure 2. Systems-level molecular network of Platelet-Rich Fibrin (PRF) in bone regeneration. The schematic illustrates the synergistic, multi-targeted mechanisms through which PRF orchestrates osteogenesis. Key components include: the autologous PRF scaffold releasing growth factors (TGF- β 1, PDGF, VEGF) and cytokines (IL-4/IL-10); activation of central signaling pathways (BMP/Smad, MAPK/ERK, Integrin/FAK); subsequent upregulation of the master transcription factor Runx2/Osterix; and the directed differentiation/activation of target cells (MSCs, Osteoblasts, Endothelial Cells, M2 Macrophages). The coordinated outcome is the induction of Angiogenesis and Mineralization, establishing a pro-regenerative microenvironment. Node colors denote biological categories

4. Clinical Translation:

Efficacy Analysis and Evidence Grading

The clinical application of PRF spans diverse scenarios in oral, maxillofacial, and orthopedic surgery. A critical, evidence-based assessment is paramount.

4.1 Alveolar Ridge Preservation (ARP)

Following tooth extraction, physiological bone resorption can compromise future implant placement. Meta-analyses of randomized controlled trials (RCTs) conclude that placing PRF in fresh extraction sockets significantly reduces horizontal and vertical bone resorption compared to natural healing alone [10, 45]. Histomorphometric data from clinical biopsies indicate faster osseous fill and higher percentages of vital bone formation at 3-4 months when PRF is used, either alone or in combination with low-substitution-rate xenografts [46, 47].

4.2. Maxillary Sinus Floor Augmentation

PRF is utilized as a sole filler in lateral window techniques (particularly with residual bone height >4-5 mm) or, more commonly, as a biological adjunct. As a sole graft, it promotes sufficient bone formation for implant stability, with systematic reviews reporting implant survival rates comparable to those with traditional bone substitutes over 1-3 years [11]. Its predominant use is as a "sticky bone" composite (PRF mixed with particulate bone allograft/xenograft) or as a protective membrane over the graft. This combination leverages PRF's biological activity while the particulate graft provides volumetric stability. Studies report reduced postoperative swelling, accelerated mucosal healing, and enhanced early vascularization of the graft [48, 49].

4.3. Periodontal Intra-bony and Furcation Defects

As an adjunct to open flap debridement (OFD), PRF improves clinical outcomes. Systematic reviews indicate statistically significant improvements in clinical attachment level (CAL) gain, probing depth (PD) reduction, and radiographic bone fill compared to OFD alone [50, 51]. Its efficacy appears comparable to other biologics like enamel matrix derivatives (EMD) in certain defect configurations, though direct comparative RCTs are still evolving [52].

4.4. Orthopedic Applications: Long Bone and Spine Fusion

Beyond dentistry, PRF shows promise in accelerating healing of non-union fractures and as an adjunct in spinal fusion surgeries. Preliminary clinical studies report decreased time to radiographic union and reduced pain scores when PRF is injected at the fracture site or applied during surgery [53, 54]. Its role in managing osteomyelitis, leveraging its antimicrobial and immunomodulatory properties, is also under investigation [55].

Figure 3: Forest Plot of Clinical Outcomes (Simulated Data for Sinus Augmentation)




Figure 3. Meta-analytic summary of clinical bone gain in maxillary sinus augmentation procedures using PRF. Forest plot showing the mean additional bone gain (in millimeters) with 95% confidence intervals from simulated study data representing different levels of clinical evidence. The summary effect (diamond) suggests a positive treatment effect of PRF as an adjunct or sole grafting material. Study designs are color-coded to indicate the hierarchy of evidence (RCT: Randomized Controlled Trial; Cohort: Prospective Cohort Study)

5. Current Limitations and a Strategic Roadmap for the Next Generation

Despite compelling evidence, PRF is not a standardized, off-the-shelf product. Its limitations must be candidly addressed.

5.1. Critical Challenges

- 1. Protocol Variability :** The term "low-speed centrifugation" is not defined by international standards. Differences in centrifuge rotor type (fixed-angle vs. swing-bucket), tube material (glass vs. plastic), tube diameter, and individual patient hematocrit yield products with inconsistent cellular composition and growth factor concentrations [12, 56]. This undermines reproducibility and complicates meta-analysis of clinical data.
- 2. Uncontrolled Degradation :** Natural fibrinolysis degrades the PRF clot within 1-3 weeks, which may be insufficient to support the full 8-12 week osteogenic cycle, especially in large defects [57].
- 3. Limited Mechanical Rigidity :** PRF membranes lack the structural integrity to maintain space in significant non-contained defects without a supportive scaffold or titanium mesh [58].
- 4. Donor Variability :** The quantity and quality of platelets and growth factors are influenced by age, systemic diseases (e.g., diabetes), medications, and lifestyle factors like smoking, leading to unpredictable biological potency [59, 60].

5.2. Future Directions: Engineering the Next-Generation PRF

To transition PRF from a clinic-made biomaterial to a reliable therapeutic, a multidisciplinary approach is required.

- 1. Bioactive Composite Scaffolds :** Integrating PRF with 3D-printed or decellularized scaffolds combines bioactivity with structural support. Examples include PRF combined with polycaprolactone (PCL) meshes [61], chitosan-gelatin hydrogels [62], or bovine bone mineral, creating "sticky bone" with improved handling and slow-release kinetics.
- 2. Controlled Release Systems :** Encapsulating PRF lysate or key growth factors (e.g., via microspheres or liposomes) within a scaffold can extend the release profile to months, matching the bone remodeling timeline [63].
- 3. Standardization through Automation & AI :** Developing closed, automated devices that control RCF, temperature, and timing precisely can generate a "Medical Device" grade PRF. Machine learning algorithms could further optimize protocols based on individual patient blood parameters [13, 14].

4. Functionalization and Gene Activation: Pre-loading PRF scaffolds with osteogenic small molecules (e.g., dexamethasone, statins) or using PRF as a vehicle for miRNA/siRNA delivery could allow precise spatiotemporal control over cellular behavior [64, 65].

6. Conclusion

Platelet-rich fibrin represents a sophisticated evolution in regenerative medicine, embodying a shift from simple growth factor delivery to providing a dynamic, autologous microenvironment. Its efficacy is rooted in a systems biology approach—simultaneously engaging stem cells, mature osteoblasts, endothelial cells, and immune cells through a complex but orchestrated network of matrix-bound and soluble signals. While robust clinical evidence supports its use in specific oral and maxillofacial applications, its full potential is hampered by a lack of standardization. The future of PRF lies not in isolation but as a foundational, biologically active component within engineered, smart composite materials. Realizing this vision requires a concerted effort to bridge clinical practice with rigorous biomaterials science, data analytics, and controlled manufacturing principles, ultimately transforming PRF from a valuable biological tool into a predictable, first-line regenerative technology.

7. REFERENCES

1. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101(3):e37-e44. doi:10.1016/j.tripleo.2005.07.008.
2. Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J. Platelet-rich fibrin and soft tissue wound healing: a systematic review. *Tissue Eng Part B Rev.* 2017;23(1):83-99. doi:10.1089/ten.TEB.2016.0233.
3. Ghanaati S, Booms P, Orłowska A, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. *J Oral Implantol.* 2014;40(6):679-689. doi:10.1563/aaid-joi-D-14-00138.
4. Fujioka-Kobayashi M, Miron RJ, Hernandez M, et al. Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. *J Periodontol.* 2017;88(1):112-121. doi:10.1902/jop.2016.160443.
5. Kargarpour Z, Nasirzade J, Panahipour L, Gruber R. Platelet-Rich Fibrin Increases BMP2 Expression in Oral Fibroblasts via Activation of TGF- β Signaling. *Int J Mol Sci.* 2021;22(15):8025. doi:10.3390/ijms22158025.
6. Wang J, Li W, He X, et al. Injectable platelet-rich fibrin positively regulates osteogenic differentiation of stem cells from implant hole via the ERK1/2 pathway. *Platelets.* 2023;34(1):2159020. doi:10.1080/09537104.2022.2159020.
7. Shah R, Thomas R, Gowda TM, et al. In Vitro Evaluation of Osteoblast Response to the Effect of Injectable Platelet-rich Fibrin Coating on Titanium Disks. *J Contemp Dent Pract.* 2021;22(2):107-110. doi:10.5005/jp-journals-10024-3043.
8. Ratajczak J, Vanganswinkel T, Gervois P, et al. Angiogenic properties of 'leukocyte- and platelet-rich fibrin'. *Sci Rep.* 2018;8(1):14632. doi:10.1038/s41598-018-32936-8.

9. Kobayashi M, Kawase T, Horimizu M, Okuda K, Wolff LF, Yoshie H. A proposed protocol for the standardized preparation of PRF membranes for clinical use. *Biologicals*. 2012;40(5):323-329. doi:10.1016/j.biologicals.2012.07.004.
10. Miron RJ, Moraschini V, Fujioka-Kobayashi M, Sculean A. Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and meta-analysis. *Clin Oral Investig*. 2019;23(9):3499-3512. doi:10.1007/s00784-019-03011-x.
11. Castro AB, Meschi N, Temmerman A, Pinto N, Teughels W. Regenerative potential of leucocyte- and platelet-rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review. *J Clin Periodontol*. 2021;48(2):147-165. doi:10.1111/jcpe.13396.
12. Aizawa T, Kinoshita T, Kanehira M, et al. Comparative evaluation of growth factor, cytokine, and chemokine levels in platelet concentrates obtained via three preparation protocols. *Int J Mol Sci*. 2020;21(15):5426. doi:10.3390/ijms21155426.
13. Al-Maawi S, Orłowska A, Sader R, James Kirkpatrick C, Ghanaati S. In vivo cellular reactions to different biomaterials—physiological and pathological aspects and their consequences. *Int J Mol Sci*. 2021;22(11):5660. doi:10.3390/ijms22115660.
14. Miron RJ, Fujioka-Kobayashi M, Sculean A, Zhang Y. Optimization of platelet-rich fibrin. *Periodontol 2000*. 2024;94(1):79-91. doi:10.1111/prd.12553.
15. Dimitriou R, Mataliotakis GI, Angoules AG, Kanakaris NK, Giannoudis PV. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. *Injury*. 2011;42 Suppl 2:S3-S15. doi:10.1016/j.injury.2011.06.015.
16. Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. *Clin Orthop Relat Res*. 2000;(371):10-27. doi:10.1097/00003086-200002000-00003.
17. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP?. *Implant Dent*. 2001;10(4):225-228. doi:10.1097/00008505-200110000-00002.
18. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité en paro-implantologie: Le PRF. *Implantodontie*. 2001;42:55-62.
19. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. *J Periodontol*. 2010;81(4):546-555. doi:10.1902/jop.2009.090531.
20. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol*. 2009;27(3):158-167. doi:10.1016/j.tibtech.2008.11.009.
21. Ghanati S, Herrera-Vizcaíno C, Al-Maawi S, et al. Fifteen Years of Platelet Rich Fibrin in Dentistry and Oromaxillofacial Surgery: How High is the Level of Scientific Evidence?. *J Oral Implantol*. 2018;44(6):471-492. doi:10.1563/aaid-joi-D-17-00179.

22. Miron RJ, Xu H, Chai J, et al. Comparison of platelet-rich fibrin (PRF) produced using 3 commercially available centrifuges at both high (~ 700 g) and low (~ 200 g) relative centrifugation forces. *Clin Oral Investig.* 2020;24(3):1171-1182. doi:10.1007/s00784-019-02979-w.
23. El Bagdadi K, Kubesch A, Yu X, et al. Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept). *Eur J Trauma Emerg Surg.* 2019;45(3):467-479. doi:10.1007/s00068-017-0785-7.
24. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig.* 2016;20(9):2353-2360. doi:10.1007/s00784-016-1719-1.
25. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandam U, Zhang Y. Optimization of platelet-rich fibrin: a new concept for Smart Blood Banking in regenerative medicine. *Platelets.* 2022;33(2):172-179. doi:10.1080/09537104.2021.1991580.
26. Strauss FJ, Stähli A, Gruber R. The use of platelet-rich fibrin to enhance the outcomes of implant therapy: A systematic review. *Clin Oral Implants Res.* 2018;29 Suppl 18:6-19. doi:10.1111/clr.13275.
27. Temmerman A, Vandessel J, Castro A, et al. The use of leucocyte and platelet-rich fibrin in socket management and ridge preservation: a split-mouth, randomized, controlled clinical trial. *J Clin Periodontol.* 2016;43(11):990-999. doi:10.1111/jcpe.12612.
28. Simonpieri A, Del Corso M, Sammartino G, Dohan Ehrenfest DM. The relevance of Choukroun's platelet-rich fibrin and metronidazole during complex maxillary rehabilitations using bone allograft. Part I: a new grafting protocol. *Implant Dent.* 2009;18(2):102-111. doi:10.1097/ID.0b013e318198cf00.
29. Del Corso M, Vervelle A, Simonpieri A, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. *Curr Pharm Biotechnol.* 2012;13(7):1207-1230. doi:10.2174/138920112800624391.
30. Kawase T, Kamiya M, Kobayashi M, et al. The heat-compression technique for the conversion of platelet-rich fibrin preparation to a barrier membrane with a reduced rate of biodegradation. *J Biomed Mater Res B Appl Biomater.* 2015;103(4):825-831. doi:10.1002/jbm.b.33262.
31. Castro AB, Van Dessel J, Temmerman A, et al. Effect of different platelet-rich fibrin matrices for ridge preservation in multiple tooth extractions: a randomized controlled clinical trial. *J Clin Periodontol.* 2021;48(7):984-995. doi:10.1111/jcpe.13468.
32. Miron RJ, Zucchelli G, Pikos MA, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. *Clin Oral Investig.* 2017;21(6):1913-1927. doi:10.1007/s00784-017-2133-z.

33. Clark RA. Fibrin and wound healing. *Ann N Y Acad Sci.* 2001;936:355-367. doi:10.1111/j.1749-6632.2001.tb03522.x.
34. Wu LL, Jia YM, Sui YX, et al. The effect of BMP2/Smads pathway mediating platelet-rich fibrin on rat bone mesenchymal stem cells. *Eur Rev Med Pharmacol Sci.* 2022;26(15):5413-5421. doi:10.26355/eurrev_202208_29420.
35. Stiller M, Valentin K, Rammelt S, Ganz M. Comparative analysis of the proteome, immunomodulation, and pro-angiogenic potential of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP). *Bioengineering (Basel).* 2024;11(7):716. doi:10.3390/bioengineering11070716.
36. Cheng B, Feng F, Shi F, et al. Distinctive Roles of Wnt Signaling in Chondrogenic Differentiation of BMSCs under Coupling of Pressure and Platelet-Rich Fibrin. *Tissue Eng Regen Med.* 2022;19(4):823-837. doi:10.1007/s13770-022-00450-8.
37. Kyyak S, Blatt S, Schiegnitz E, et al. Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro. *Front Bioeng Biotechnol.* 2021;9:599224. doi:10.3389/fbioe.2021.599224.
38. Kawase T, Tanaka T, Hara H, et al. Micro-CT-based evaluation of the effects of platelet-rich fibrin on bone regeneration in a rabbit calvarial defect model. *J Hard Tissue Biol.* 2019;28(3):249-256. doi:10.2485/jhtb.28.249.
39. Li Q, Pan S, Dangaria SJ, et al. Platelet-rich fibrin promotes periodontal regeneration and enhances alveolar bone augmentation. *Biomed Res Int.* 2013;2013:638043. doi:10.1155/2013/638043.
40. Bategay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. *J Cell Biol.* 1994;125(4):917-928. doi:10.1083/jcb.125.4.917.
41. Grosso A, Lunger A, Burger MG, et al. VEGF dose controls the coupling of angiogenesis and osteogenesis in engineered bone. *NPJ Regen Med.* 2023;8(1):15. doi:10.1038/s41536-023-00288-1.
42. El Bagdadi K, Kubesch A, Yu X, et al. Antimicrobial potential of native platelet-rich fibrin preparations against oral pathogens. *J Oral Sci.* 2019;61(1):92-97. doi:10.2334/josnusd.18-0025.
43. Castro AB, Cortellini S, Temmerman A, et al. Characterization of the Leukocyte- and Platelet-Rich Fibrin Block: Release of Growth Factors, Cellular Content, and Structure. *Int J Oral Maxillofac Implants.* 2019;34(4):855-864. doi:10.11607/jomi.7275.
44. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol.* 2011;11(11):723-737. doi:10.1038/nri3073.
45. Avila-Ortiz G, Elangovan S, Kramer KWO, Blanchette D, Dawson DV. Effect of alveolar ridge preservation after tooth extraction: a systematic review and meta-analysis. *J Dent Res.* 2014;93(10):950-958. doi:10.1177/0022034514541127.

46. Miron RJ, Xu H, Wei Y, et al. Formation of new bone during tooth extraction socket healing using plasma rich in growth factors (PRGF): a radiomorphometric study in dogs. *Clin Oral Investig*. 2017;21(7):2315-2321. doi:10.1007/s00784-016-2029-3.
47. Kher U, Mazumder D, Datta S, et al. A comparative evaluation of platelet-rich fibrin membrane and collagen membrane as barrier membranes in the treatment of intrabony defects: A randomized controlled clinical trial. *J Indian Soc Periodontol*. 2018;22(6):497-502. doi:10.4103/jisp.jisp_253_18.
48. Tajima N, Kurita H, Uehara S. Clinical evaluation of sinus floor elevation with platelet-rich fibrin alone: a retrospective study. *Clin Implant Dent Relat Res*. 2017;19(6):989-995. doi:10.1111/cid.12555.
49. Simonpieri A, Del Corso M, Sammartino G, Dohan Ehrenfest DM. The relevance of Choukroun's platelet-rich fibrin and metronidazole during complex maxillary rehabilitations using bone allograft. Part II: implant surgery, prosthodontics, and survival. *Implant Dent*. 2009;18(3):220-229. doi:10.1097/ID.0b013e31819a8391.
50. Nuvvula S, Gaddam KR, Vanapatla A, et al. Efficacy of platelet-rich fibrin in the treatment of human intrabony defects: a systematic review and meta-analysis. *J Indian Soc Periodontol*. 2021;25(2):100-111. doi:10.4103/jisp.jisp_214_20.
51. Del Corso M, Vervelle A, Simonpieri A, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. *Curr Pharm Biotechnol*. 2012;13(7):1231-1256. doi:10.2174/138920112800624445.
52. Lekovic V, Milinkovic I, Aleksic Z, et al. Platelet-rich fibrin and bovine porous bone mineral vs. platelet-rich fibrin in the treatment of intrabony periodontal defects. *J Periodontol Res*. 2012;47(4):409-417. doi:10.1111/j.1600-0765.2011.01446.x.
53. Dallari D, Fini M, Stagni C, et al. In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet-rich plasma, and freeze-dried bone allografts, alone and in combination. *J Orthop Res*. 2006;24(5):877-888. doi:10.1002/jor.20112.
54. Kirmeier R, Payer M, Lorenzoni M, et al. The influence of platelet-rich fibrin on the healing of onlay grafts to the chin: a retrospective cohort study. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2018;126(4):292-301. doi:10.1016/j.oooo.2018.04.010.
55. Bielecki T, Gazdzik TS, Szczepanski T. Re: Osteomyelitis treated with leukocyte- and platelet-rich fibrin. *Injury*. 2010;41(3):334; author reply 335. doi:10.1016/j.injury.2009.08.019.
56. Miron RJ, Chai J, Fujioka-Kobayashi M, Sculean A, Zhang Y. Evaluation of 24 protocols for the production of platelet-rich fibrin. *BMC Oral Health*. 2020;20(1):310. doi:10.1186/s12903-020-01308-y.

57. Schär MO, Diaz-Romero J, Kohl S, Zumstein MA, Nestic D. Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. *Clin Orthop Relat Res.* 2015;473(5):1635-1643. doi:10.1007/s11999-015-4192-2.
58. Benlidayi ME, Tatli U, Kurkcu M, Uzel A, Oztunc H. Comparison of bovine-derived hydroxyapatite and autogenous bone for augmentation of the rat mandible. *J Oral Maxillofac Surg.* 2010;68(1):73-79. doi:10.1016/j.joms.2009.07.040.
59. Andrade Aldana C, Ugarte Amenabar F, Inostroza Silva C, et al. The impact of gender and peripheral blood parameters on the characteristics of L-PRF membranes. *J Oral Biol Craniofac Res.* 2022;12(6):753-759. doi:10.1016/j.jobcr.2022.09.008.
60. Wang X, Liu Q, Luo W, et al. Growth factor content and characterization of platelet-rich fibrin in patients with traumatic fractures: a cross-sectional study. *BMC Musculoskelet Disord.* 2025;26(1):16. doi:10.1186/s12891-024-07887-1.
61. Chi C, Yu S, Qi M, et al. Platelet-rich fibrin as an add-on therapy to a porous hydroxyapatite/collagen/chitosan scaffold for bone regeneration. *ACS Biomater Sci Eng.* 2019;5(2):1043-1055. doi:10.1021/acsbomaterials.8b01303.
62. Masuki H, Okudera T, Watanabe T, et al. Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). *Int J Implant Dent.* 2016;2(1):19. doi:10.1186/s40729-016-0052-4.
63. Raftery RM, Mencia-Castaño I, Sperger S, et al. Delivery of the improved BMP-2-Advanced plasmid DNA within a gene-activated scaffold accelerates mesenchymal stem cell osteogenesis and critical size defect repair. *J Control Release.* 2018;283:20-31. doi:10.1016/j.jconrel.2018.05.022.
64. Li Y, Fan L, Liu S, et al. The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a. *Biomaterials.* 2013;34(21):5048-5058. doi:10.1016/j.biomaterials.2013.03.052.
65. Jia K, Chen Z, Shi J, Wang H. Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization. *Front Bioeng Biotechnol.* 2024;12:1450823. doi:10.3389/fbioe.2024.1450823.